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Acetylation of the lysine residues in histones and other DNA-binding proteins plays a major role in regulation of eukaryotic gene expres-
sion. This process is controlled by histone acetyltransferases (HATs/KATs) found in multiprotein complexes that are recruited to chro-
matin by the scaffolding subunit transformation/transcription domain-associated protein (TRRAP). TRRAP is evolutionarily conserved
and is among the top five genes intolerant to missense variation. Through an international collaboration, 17 distinct de novo or appar-
ently de novo variants were identified in TRRAP in 24 individuals. A strong genotype-phenotype correlation was observed with two
distinct clinical spectra. The first is a complex, multi-systemic syndrome associated with various malformations of the brain, heart, kid-
neys, and genitourinary system and characterized by a wide range of intellectual functioning; a number of affected individuals have in-
tellectual disability (ID) and markedly impaired basic life functions. Individuals with this phenotype had missense variants clustering
around the c.3127G>A p.(Ala1043Thr) variant identified in five individuals. The second spectrummanifested with autism spectrum dis-
order (ASD) and/or ID and epilepsy. Facial dysmorphism was seen in both groups and included upslanted palpebral fissures, epicanthus,
telecanthus, a wide nasal bridge and ridge, a broad and smooth philtrum, and a thin upper lip. RNA sequencing analysis of skin fibro-
blasts derived from affected individuals skin fibroblasts showed significant changes in the expression of several genes implicated in
neuronal function and ion transport. Thus, we describe here the clinical spectrum associated with TRRAP pathogenic missense variants,
and we suggest a genotype-phenotype correlation useful for clinical evaluation of the pathogenicity of the variants.
Post-translational modifications including acetylation,
methylation, phosphorylation, and ubiquitination, of
core histones directly alter DNA-histone and histone-his-
tone interactions and thus influence nucleosome dy-
namics.1 Tight regulation of these marks is required by
cells for proper gene transcription,2 DNA repair,3 and
DNA replication. One major activator of transcription is
the acetylation of histone tails, which act by neutralizing
the positive charges of lysine residues or by recruiting chro-
matin remodelers and transcription factors.4 This tightly
regulated process is performed by histone acetyltrans-
ferases (HATs) and reversed by histone deacetylases
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(HDACs). There are three major families of HATs:
Gcn5-related N-acetyltrasnferase (GNAT), MYST (MOZ,
SAS2, SAS3—also known as YBF2—and TIP60), and
p300 (EP300-CREBBP).5 The activity and localization of
most HATs, such as TIP60 or GCNL5, depend on a multi-
protein assembly that contains the scaffolding protein
transformation/transcription domain-associated protein
(TRRAP).
TRRAP is a large protein of 3,859 amino acids and is
conserved from yeast to humans. It is an ataxia-telangiec-
tasia mutated (ATM) related member of the phosphatidyli-
nositol 3-kinase-related kinase (PIKK) family.6 Like other
ATM-related members, it contains FAT (FRAP, ATM, and
TRRAP) and FATC (FRAP, ATM, and TRRAP, C terminus) do-
mains flanking a PI3/PI4-kinase domain. The kinase
domain of TRRAP does not engage in catalytic activity7
but is required for the proper recruitment of HAT
complexes.8 TRRAP has been shown to be involved in
P53-, E2F-, and c-MYC-dependent gene transcription and
oncogenic transformation.6,9,10 As stressed in cancer
studies, TRRAP plays an important role in cell-cycle regula-
tion. A recurrent somatic TRRAP variant, c.2165C>T
p.(Ser722Phe),11 has been identified in melanoma, and
the oncogenic potential of TRRAP has been identified
in glioblastoma multiforme,12 pancreatic adenocarci-
noma,13 and lymphoma.10 Furthermore, Trrap knockout
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leads to early embryonic lethality inmice through errors in
the cell cycle and a failure to arrest at the mitotic
checkpoint.14 In mouse embryonic stem cells (ESCs), Trrap
is indispensable for self-renewal as well as correct differen-
tiation,15 suggesting an essential role in embryonic devel-
opment and morphogenesis. Moreover, brain-specific
Trrap knockout in mice leads to premature differentiation
of neural progenitors and abnormal brain development
through a decrease in the expression of cell-cycle regula-
tors. This decreased expression results in brain atrophy
andmicrocephaly.16 TRRAP has previously been associated
with neuropsychiatric disorders such as schizophrenia in a
few patients.17–20 We herein provide data showing that
TRRAP pathogenic variants are associated with a variable
neurodevelopmental disorder.
Through an international collaboration and aided by the
web-based tool GeneMatcher,21 we identified 17 distinct
missense TRRAP variants with strong clinical and/or mo-
lecular evidence for pathogenicity in 24 individuals with
neurodevelopmental disorders (Table 1, Figure 1A). These
variants were identified either by trio or solo exome
sequencing (ES) from research and clinical cohorts. All
affected individuals or their guardians gave appropriate
consent for research procedures. This study was approved
by the CHU de Nantes ethics committee (comite´ consulta-
tif sur le traitement de l’information en matie`re de re-
cherche no. 14.556). Methods are described in Table S1.
These 17 variants were absent from ExAC and
gnomAD22 and were found de novo or apparently de novo
(maternity and paternity not checked) in all individuals,
except for two sisters who had inherited a variant from a
mother with low-level mosaicism (Figure S1) and an indi-
vidual whose father was unavailable but whose paternal
grandparents did not carry the variant. Three variants
were recurrently observed: p.Ala1043Thr was identified
in five individuals, and p.Glu1106Lys and p.Gly1883Arg
were each identified in two individuals. All the variants
were predicted to be deleterious by CADD23 (scaled C
scores were over 20), and they were variously predicted
to be pathogenic by SIFT24 and PolyPhen-2 HVAR.25 As
shown in Figure 2A, the 17 variants seen in the individuals
we studied had significantly increased CADD scores
compared to the scores for singleton missense variants re-
ported in gnomAD.
The 17 variants all occurred at residues conserved among
vertebrates (Figure 1B) and in regions depleted in missense
variants in gnomAD. Indeed, when we assessed missense
tolerance ratios for TRRAP, we observed that most of the
17 variants were in regions intolerant to missense variants
(Figure 2B). Nine out of the 17 variants occurred at highly
mutable CpG sites, including one within the codon that
leads to the recurrent p.Ala1043Thr variant observed in
five individuals. Six missense variants with lesser evidence
for pathogenicity were found in another six unrelated indi-
viduals (individuals 25 to 30 in Table S1). These variants
might be deleterious but were not clearly pathogenic:
perhaps the inheritance pattern could not be determined;
the variant was present in gnomAD or led to another
missense change at the same residue as a variant reported
in gnomAD; or the variant was located in a less conserved
region of TRRAP (Table S2).
Given the number of de novo variants identified, the
enrichment for TRRAP de novo variants in our study
was calculated as (p ¼ 4.2 3 106) on the basis of denovo-
lyzer.26 Nevertheless, the current number of 22 detected de
novo variants in TRRAP is not of genome-wide significance
(p ¼ 0.08) after correction for the following: (a) 19,000
protein-coding genes, (b) 22,898 trios studied, and (c) the
underlying mutability of the full-length protein-coding
TRRAP transcript. However, this statistical calculation
does not take into account the spatial distribution of the
variants. Indeed, three-dimensional modeling of human
TRRAP structure inferred from the orthologous Saccharo-
myces cerevisiae protein Tra1 (Figure 2C) suggested a clus-
tering of the variants in different regions of TRRAP. The
most important clustering was observed for 13 variants be-
tween codons 1031 and 1159. Interestingly, when visual-
ized in 3D, these variants localized near one another
(Figure 1C), revealing a domain of TRRAP with a poten-
tially novel specific function, although this domain has
not yet been characterized. We performed a statistical clus-
tering analysis comparing the mean distance between
observed variants to ten million permutations of random
variants, as previously described.27 This analysis revealed
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a significant clustering of variants along the primary
sequence of TRRAP (p value ¼ 9 3 108), suggesting a
model in which specific domains are affected and haploin-
sufficiency is unlikely, at least for clustering variants.
Among the 24 individuals who carried pathogenic vari-
ants, 19 presented with facial dysmorphisms. Recurrent
features that were noted among these individuals included
upslanted palpebral fissures, epicanthus, telecanthus, a
wide nasal bridge and ridge, a broad and smooth philtrum,
and a thin upper lip (Figure 3). We performed a computer-
assisted facial gestalt visualization,28,29 which highlighted
several of these features, particularly for individuals with
variants clustering with the recurrent p.Ala1043Thr
variant (Figure 3R). All the individuals had developmental
delay, although the severity of intellectual disability (ID)
was highly variable. Whereas most individuals had
apparent ID with markedly impaired basic life functions,
some of them presented with mild ID or even no cognitive
deficits (Table 2 and Table S3). Peripheral neuropathy was
also noted; it was severe in one individual and consisted
of lower-limb hyperreflexia in five other individuals.
In addition to alteration in cerebral function, some
individuals showed brain, cerebellum, heart, kidney, or
urogenital malformations. We observed a strong geno-
type-phenotype correlation (Figure1A,Table 2); thehighest
incidence of malformations was seen in 13 individuals
whose variants cluster in the region of the predicted
protein from codons 1031 to 1159: c.3093T>G
(p.Ile1031Met), c.3104G>A (p.Arg1035Gln), c.3111C>A
(p.Ser1037Arg), c.3127G>A (p.Ala1043Thr), c.3311A>G
(p.Glu1104Gly), c.3316G>A (p.Glu1106Lys), c.3331G>T
(p.Gly1111Trp), and c.3475G>A (p.Gly1159Arg). In
contrast, individuals with variants residing outside of this
region had less malformation and presented mainly with
autism spectrum disorder (ASD) and/or ID, sometimes
associated with epilepsy. Variants in these individuals
were more dispersed along the protein, although
some, including c.5575C>T (p.Arg1859Cys), c.5596T>A
(p.Trp1866Arg), c.5598G>T (p.Trp1866Cys), c.5647G>A
(p.Gly1883Arg), and c.5795C>T (p.Pro1932Leu), appar-
ently aggregated in another region.
13 individuals with variants in the codon 1031–1159 re-
gion had global developmental delay and apparent ID,
ranging from speech delay and learning difficulties to
markedly impaired basic life functions (Table 2 and
Table S3). The last available occipitofrontal-circumference
measurements revealed microcephaly (ranging from 2.8
to 5 standard deviations [SDs]) in 46% (6/13) of individ-
uals. Cerebral magnetic resonance imaging (MRI) had been
performed in 10 out of 13 individuals, and seven of those
10 (70%) showed structural brain anomalies, including
cerebellar vermis hypoplasia (6/10), ventricular enlarge-
ment (3/10), cortical atrophy (2/10), brainstem atrophy
(2/10), polymicrogyria (1/10), focal gliosis (1/10), delayed
Table 1. De Novo TRRAP Variants Identified in 24 Individuals
cDNA Protein Inheritance CpG gnomAD
CADD Phred
Score (v1.3) SIFT PolyPhen2 HVAR
Number of
Individuals
c.2413C>T p.Leu805Phe de novo no absent 28.2 deleterious (0) probably damaging (0.998) 1
c.2580C>G p.Phe860Leu de novo no absent 27.6 deleterious (0.03) possibly damaging (0.867) 1
c.2678G>T p.Arg893Leu apparently
de novo
yes absent 34 deleterious (0) probably damaging (0.986) 1
c.3093T>G p.Ile1031Met de novo no absent 23.4 deleterious (0.02) benign (0.308) 1
c.3104G>A p.Arg1035Gln de novo yes absent 23.9 tolerated (0.09) benign (0.404) 1
c.3111C>A p.Ser1037Arg de novo yes absent 23.7 tolerated (0.14) possibly damaging (0.656) 1
c.3127G>A p.Ala1043Thr de novo yes absent 23.2 tolerated (0.27) benign (0.066) 5
c.3311A>G p.Glu1104Gly de novo no absent 24.6 deleterious (0.04) probably damaging (0.91) 1
c.3316G>A p.Glu1106Lys de novoa no absent 27.7 deleterious (0) possibly damaging (0.816) 2
c.3331G>T p.Gly1111Trp apparently
de novo
yes absent 34 deleterious (0) probably damaging (0.999) 1
c.3475G>A p.Gly1159Arg de novo no absent 33 deleterious (0) probably damaging (0.999) 1
c.5575C>T p.Arg1859Cys de novo yes absent 34 deleterious (0) probably damaging (0.997) 1
c.5596T>A p.Trp1866Arg de novo no absent 28.7 deleterious (0) probably damaging (0.999) 1
c.5598G>T p.Trp1866Cys de novo no absent 33 deleterious (0) probably damaging (0.999) 1
c.5647G>A p.Gly1883Arg de novo yes absent 33 deleterious (0) probably damaging (1) 2
c.5795C>T p.Pro1932Leu germline
mosaicism
yes absent 35 deleterious (0) probably damaging (0.997) 2
c.11270G>A p.Arg3757Gln de novo yes absent 28.6 deleterious (0.01) benign (0.269) 1
The RefSeq transcript used for TRRAP is RefSeq: NM_001244580.1. Apparently de novowas mentioned when paternity andmaternity were not checked. a. For one
individual with p.(Glu1106Lys), father was unavailable, paternal grandparents were tested and did not carry the variant.
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myelination (1/10), and corpus callosum hypoplasia
(1/10). Neurological examination revealed hypotonia in
31% (4/13) of individuals. Only one individual was re-
ported to have epilepsy. Seven individuals (54%) were re-
ported to require feeding exclusively by gastrostomy
tube. Among the 10 individuals who were examined by
echocardiography, 70% (7/10) had abnormal results, 50%
(5/10) had ventricular septal defects, 30% (3/10) had pat-
ent ductus arteriosus, 30% (3/10) had patent foramen
ovale, 20% (2/10) had pulmonary hypertension, and
20% (2/10) had aortic coarctation. Abdominal ultrasound
revealed anomalies in 70% (7/10) of individuals in which
it was performed. Abnormal renal morphology, namely
multicystic dysplastic kidney, hydronephrosis, a duplicate
kidney, and/or a small kidney, was described in 60% (6/10)
of individuals, and vesicoureteral reflux was also observed
in 30% (3/10) of these individuals. Individual 15 presented
with a large left-sided posterolateral congenital diaphrag-
matic hernia (Table S3). Hernias of the abdominal wall
were also found in 23% (3/13) of individuals and included
an umbilical hernia, an omphalocele, and an inguinal her-
nia. Three males (3/6; 50%) had external-genitalia anoma-
lies, including microphallus, hypoplastic scrotum, and
cryptorchidism, and two females (2/7; 29%) had a dupli-
cated vagina and/or uterus. Other observed anomalies
included dysplastic nails (8/13; 62%), cleft lip and palate
(5/13; 38%), clinodactyly of the fifth finger (4/13; 31%),
laryngotracheomalacia (3/13), accessory nipple (3/13;
23%), bilateral cutaneous syndactyly of the second and
third toe (2/13; 15%), and anomalies of the lacrimal glands
(1/13; 8%; see also below with regard to individuals
1 and 19). Four individuals (4/13; 31%) had visual impair-
ment, and three (3/13; 23%) had hearing impairment.
Hearing impairment was associated with inner-ear malfor-
mations in two cases. Recurrent infections, mainly respira-
tory and urinary-tract infections, affected three out of 13
(23%) individuals. Individual 9 died at 12 years of age in
the context of multiple co-morbidities, including renal
failure with acute fluid fluctuations, tracheostomy for
severely obstructive laryngotracheomalacia, intermittent
supraventricular tachycardia, arterial insufficiency, and
polyendocrinopathy (insulin-dependent diabetes, adrenal
insufficiency, and hypothyroidism).
Among individuals with variants falling outside of the
1031–1159 region, 5/11 (45%) were diagnosed with ASD,
and another three individuals (3/11; 27%) had some find-
ings of ASD but no formal diagnosis. 8/11 (73%) had devel-
opmental delay and mild-to-severe ID, and three had
speech delay, but their IQs were measured above 70, and
two of these IQs were in the normal range. Four individuals
(4/11; 36%) had various types of epilepsy, namely absence
and tonic-clonic seizures, or Lennox-Gastaut syndrome.
The age of seizure onset ranged from 2 to 10 years old. Mal-
formations were infrequent in this group overall, although
Figure 1. Genotype-Phenotype Correlation Associated with TRRAP Variants
(A) Predicted de novo and apparently de novo variants in affected individuals are represented on the TRRAP protein. The variants in red
represent individuals with apparent ID andmalformations, the variants in purple represent individuals with isolated ID with or without
ASD, and the variants in blue represent individuals with only ASD and an IQ above 70. If more than one individual was heterozygous for
the variant, the number of affected individuals is indicated in the circle. Adapted from ProteinPaint.55
(B) Amino acid conservation of each mutated residue. The overall amino acid similarity with the human sequence is shown on the left.
(C) Homology model of human TRRAP (GenBank: NP_001231509.1) predicted by PHYRE2 Protein Fold Recognition Server56 repre-
sented by UCSF Chimera.57 Mutated residues in the 1031–1159 cluster are shown. Abbreviations are as follows: FAT—FRAP, ATM,
and TRRAP; PIKK-like—phosphatidylinositol 3-kinase-related protein kinase-like; and FATC—FRAP, ATM, and TRRAP C-terminal.
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individual 2 had microcephaly and heart malformations,
individual 1 had lacrimal duct aplasia, individual 19 had
lacrimal duct aplasia and optic disc colobomas, and indi-
vidual 21 had a postaxial polydactyly of one hand.
TRRAP-associated chromatin remodeling complexes are
generally associated with gene activation,30 which is
consistent with their HAT activity. Nevertheless, the
NuA4 complex has been shown to have a gene-repression
activity necessary for ESC pluripotency.31,32 This gene-
repression activity seems to be independent from its lysine
acetyltransferase activity.33 To test the hypothesis that
TRRAP variants alter gene expression, we obtained skin
fibroblasts from two individuals, individual 1, with
p.Leu805Phe, and individual 19, with p.Trp1866Cys and
performed next-generation sequencing with technical
replicates of RNA (i.e., separately prepared libraries from
the same samples). The RNA library preparation and
sequencing as well as bioinformatics analysis methods
can be found in the Supplemental Data. We found that,
in comparison to two typically developing individuals
(controls), both individuals with TRRAP variants
had remarkably different gene expression patterns
(Figure S2A). Interestingly, most differentially expressed
genes (DEGs) analyzed with DESeq2 were upregulated in
affected individuals compared to controls (Figure S2B).
Moreover, the individual with p.Leu805Phe had 619
Figure 2. TRRAP Sequence Is Intolerant to Missense Variants
(A) CADD scores of the 17 variants identified in affected individuals are compared to scores for gnomAD singleton missense variants. In
order to avoid CADD training circularity, we compared the individuals’ variants to variants seen once in gnomAD.
(B) TRRAPmissense tolerance ratio (MTR) plot. TheMTR is a statistic that quantifies the extent of purifying selection that has been acting
specifically against missense variants in the human population. For TRRAP, we adopted the 21-codon sliding window and used exome-
sequencing standing-variation data in the gnomAD database, version 2.0. MTR data were downloaded from Missense Tolerance Ratio
(MTR) Gene Viewer (see Web Resources). An MTR ¼ 1 (blue dashed line) represents neutrality (i.e., observing the same proportion of
missense variants in the window as expected on the basis of the underlying sequence context). Red segments of the MTR plot have
achieved exome-wide FDR<0.10 for a significance test of a window’s deviation from MTR ¼ 1. The black dashed line signifies gene-spe-
cific medianMTR, the brown dashed line signifies gene-specific 25th centile MTR, and the orange dashed line signifies gene-specific fifth
centile MTR. The locations of our 23 case-ascertained de novo variants are denoted by red stars along TRRAP’s MTR plot. The 17 different
variants are numbered within circles as follows: (1) p.Leu805Phe; (2) p.Phe860Leu; (3) p.Arg893Leu; (4) p.Ile1031Met; (5) p.Arg1035Gln;
(6) p.Ser1037Arg; (7) p.Ala1043Thr; (8) p.Glu1104Gly; (9) p.Glu1106Lys; (10) p.Gly1111Trp; (11) p.Gly1159Arg; (12) p.Arg1859Cys;
(13) p.Trp1866Arg; (14) p.Trp1866Cys; (15) p.Gly1883Arg; (16) p.Pro1932Leu; and (17) p.Arg3757Gln. We found that de novo variants
were significantly enriched in the intolerant 50% of TRRAP’s protein-coding sequence; 18 (78%) of the 23 de novo events affected the
most intolerant 50% of the TRRAP sequence (binomial exact test p ¼ 0.01). Strikingly, only the most recurring de novomissense variant
(GenBank: NM_001244580.1 p. Ala1043Thr) resided outside of the intolerant TRRAP sequence.
(C) Localization of the mutated TRRAP residues on 3D protein models including 14 out of 17 likely pathogenic variants and two out of
six additional variants of unknown significance are shown. The representation of the structure of human TRRAP (GenBank:
NP_001231509.1) was predicted by PHYRE2 Protein Fold Recognition Server by comparison to its Saccharomyces cerevisiae ortholog, ac-
cording to the cryo-EM structure of the SAGA (Spt-Ada-Gcn5-acetyltransferase) andNuA4 coactivator subunit Tra1 present in the protein
data bank (PDB: 5OJS). Variants in regions non-homologous to Tra1 are not represented. Structure representation was made with UCSF
Chimera.
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Figure 3. Photographs of Individuals with TRRAP Variants
(A) Individual 1 at the age of 8 years. Note the telecanthus, broad nasal bridge, widely spaced eyes, relatively thin upper vermilion, flared
eyebrows, and ectropion.
(legend continued on next page)
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DEGs; the Log2 fold change (Log2FC) was higher than 2 or
lower than 2, and the p value was adjusted for 10% false
discovery rate lower than 0.01 (padj) (Supplemental Data,
Table S5).
To identify genes with significant expression differences,
we performed differential gene expression analysis be-
tween the two individuals with TRRAP variants (combined
as biological replicates) and two unaffected controls. Gene
ontology (GO) enrichment analysis of these genes with the
GOrilla web application indicates an enrichment for the
adrenergic receptor signaling pathway, genes important
for neurological function, and potassium and ATP-
sensitive ion transporters (Figure S2B, Supplemental
Data, Table S5). The two individuals who were tested car-
ried variants outside the cluster associated with the more
syndromic ID; if there are distinct effects on gene regula-
tion, it will be worth comparing gene expression between
the two groups. Finally, because it has been shown that
TRRAP has direct interactions with different partners not
related to the HAT complex, we cannot exclude the possi-
bility that the transcriptome alteration might be caused by
a mechanism other than impaired HAT activity. Thus, we
highlighted candidate pathways that might be useful for
uncovering the pathomechanism of TRRAP variants in
future studies.
TRRAP acts as a scaffold in HAT complexes. Although it
does not have a direct role in acetylation, we hypothesize
that pathogenic effects of variants might be due to dysre-
gulation of acetylation, a major process that has been
associated with several neurodevelopmental disorders.34
Pathogenic variants of KAT6B (MIM: 605880) cause both
Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS
[MIM: 603736])35–37 and genitopatellar syndrome (GPS
[MIM: 606170]),38,39 and pathogenic variants in KAT6A
and BRPF1 mutations have also been associated with a
neurodevelopmental disorder.40–42 Rubinstein-Taybi syn-
drome (MIM: 180849 and 613684) is associated with vari-
ants in HAT-complex-encoding genes, namely CREBBP
and EP300.43–46 In addition to cognitive impairment,
abnormal histone acetylation can also result in behavioral
disorders, as evidenced by the associations found between
non-syndromic ASD and/or schizophrenia and alterations
in several lysine acetyltransferase and lysine deacetylase
genes, including BRD1, HDAC4, HDAC6, and
HDAC9.34,47–50
Variants in TRRAPwere associated with neuropsychiatric
disorders, including childhood disintegrative disorder,17
schizophrenia,18,19 and ASD.20 The ASD report included
individuals 18 and 19, who had p.Trp1866Arg and
p.Trp1866Cys, respectively. We thus confirmed the associ-
ation with ASD and provide evidence that it can be found
either isolated or associated with ID. On the basis of the
ExAC dataset alone without studies on neuropsychiatric
disorders, TRRAP is in the top five human genes that are
most intolerant of missense variants: it has a missense
z-score of 10.1.22 Although this study includes only the
first 24 identified individuals, a strength of the study is
that it was primarily ascertained by sequencing, reducing
phenotypic ascertainment bias. Given the highly con-
strained region of the observed variants coupled with the
population constraint and evolutionary conservation, we
hypothesize that variants outside of these regions are likely
to be associated with prenatal lethality, although we
cannot exclude the possibility that milder phenotypes
might be underrepresented in current exome datasets. It
is worth noting that we exclusively identifiedmissense var-
iants in the affected individuals. Given the loss-of-function
(LoF) intolerance of TRRAP in ExAC (pLI¼ 1.00), we would
(B) Individual 5 at the age of 8.5 years. Note the wide mouth, thin upper lip, and widely spaced eyes with a wide and depressed nasal
bridge.
(C) Individual 6 at the age of 29 years. Note the sparse eyebrows, upslanting palpebral fissures, smooth philtrum, thin upper lip, and low
columella.
(D) Individual 9 at the age of 11 years. Note the deeply set eyes, sparse eyebrows, and wide nasal bridge.
(E) Individual 8. Note the telecanthus, low-set ears with upturned earlobes, and, on the fourth picture from the left, the single transverse
palmar crease.
(F) Individual 12 at the age of 5 years. Note the prominent forehead, arched eyebrows, short palpebral fissures, epicanthal folds,
depressed nasal bridge, and thick upper vermilion.
(G) Individual 13 at the age of 14 years. Note the upslanted palpebral fissures and prominent forehead.
(H) Individual 10 at the ages of 1 month, 16 months, and 3 years. Note the cleft lip and palate, wide mouth, epicanthic fold, progna-
thism, and supernumerary nipples.
(I) Individual 15 at the age of 12 years. Note the wide nasal bridge and upslanting palpebral fissures.
(J) Individual 19 at the ages of 2.5 years and 8 years. Note folded-down upper eyelid and sparse medial eyebrows.
(K) Individual 16 at the age of 2 years. Note the prominent forehead, epicanthic fold, telecanthus, flat nasal bridge, and low-set ears.
(L) Individual 20 at the age of 10 years. Note the widely spaced eyes, telecanthus, wide nasal bridge and ridge, and thin upper vermilion.
(M) Individual 18. Note the narrow nose, flared eyebrows, almond-shaped eyes with hypoplastic infraorbital ridges, telecanthus, smooth
philtrum, and small, low-set, and posteriorly rotated ears.
(N) Individual 21. Note the short palpebral fissures, epicanthal folds, and thin upper vermilion.
(O) Individual 22 at the age of 24 years. Note the broad nasal bridge, deeply set eyes, upslanted palpebral fissures, widely spaced eyes, and
posteriorly rotated ears.
(P) Individual 23 at the age of 19 years. Note the deeply set eyes, upslanted palpebral fissures, widely spaced eyes, epicanthal folds, and
posteriorly rotated ears.
(Q) Individual 24. Note the smooth philtrum and wide nasal ridge.
(R) Average facial gestalt visualization of nine healthy age- and gender-matched controls on the left; on the right, nine individuals with
variants in the 1031–1159 cluster. Facial images are flipped and aligned to preserve bilateral asymmetry.
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expect to identify at least some LoF variants if haploin-
sufficiency of TRRAP was the causal mechanism. In
DECIPHER (accessed May 14, 2018), no small or intragenic
deletions involving TRRAP have been identified. Thus,
when the significant clustering is taken into account, our
results suggest that missense variants might act either as
gain-of-function or dominant-negative variants and that
haploinsufficiency of TRRAP is likely to be prenatally le-
thal, although we cannot exclude the possibility that an
LoF effect of non-clustering variants is associated with a
milder phenotype.
TRRAP participates in embryonic development, as
demonstrated by its binding with proteins regulating the
Notch signaling pathway in fruit fly51, the Ras signaling
pathway in C. elegans52, or the Wnt53 signaling pathway
in 293T cells.53 Therefore we suspect that TRRAP variants,
more especially those falling within the 1031–1159 region,
perturb the interactions with at least one of these develop-
mental signaling pathways; such a perturbance would
explain the multiple malformations observed in about
half of the affected individuals.
In yeast, a series of 100 codon deletion mutants in the
ortholog tra1 showed reduced or complete loss of
viability.54 Most deletions impaired coactivator complex
assembly, notably the ones encompassing the homolo-
gous 1031–1159 cluster (mutants D13–D14), as well as
the regions homologous to those containing variants
p.Leu805Phe, p.Phe860Leu, and p.Arg893Leu (mutants
D11–D12) and the p.Arg3757Gln variant (mutant D39).
In contrast, mutants D21–D22 encompassing the region
homologous to the cluster associated with fewer malfor-
mations (codons 1859–1932) were viable, which might
help explain the milder clinical phenotype associated
with variants within this cluster. In mice, Trrap knockout
leads to early embryonic lethality,14 and a neural-cell-spe-
cific conditional Trrap knockout line16 revealed premature
differentiation of neural progenitors, depletion of progen-
itor pools, and a significant reduction in cortical thickness.
These mice exhibited striking microcephaly, in agreement
with what we observed in half of the individuals in our
study cohort, primarily those with variants in the 1031–
1159 cluster.
In summary, we report evidence that variants in TRRAP
are associated with a pleiotropic neurodevelopmental syn-
drome with a potential genotype-phenotype correlation.
Our functional data highlight an enrichment of genes
related to neuronal function and ion transport. This
enrichment could underline the pathophysiology of the
Table 2. Clinical Description of Individuals with Variants Inside or Outside the 1031–1159 Cluster
Symptoms All Individuals Cluster 1031–1159 Variants Outside the Cluster
Global developmental delay 24/24 (100%) 13/13 (100%) 11/11 (100%)
Intellectual disability 17/20 (85%) 11/11 (100%) 6/9 (67%)
Facial dysmorphisms 19/24 (79%) 11/13 (85%) 8/11 (73%)
Autism spectrum disorder 5/24 (21%) 0/13 (0%) 5/11 (45%)
Microcephaly (<-2.5 SD) 7/24 (29%) 6/13 (46%) 1/11 (9%)
Short stature 7/23 (30%) 4/12 (33%) 3/11 (27%)
Hypotonia 8/24 (33%) 4/13 (31%) 4/11 (36%)
Feeding difficulties 8/24 (33%) 7/13 (54%) 1/11 (9%)
Seizures 5/24 (21%) 1/13 (8%) 4/11 (36%)
Cleft lip and palate 5/24 (21%) 5/13 (38%) 0/11 (0%)
Cerebellar hypoplasia 6/18 (33%) 6/11 (55%) 0/7 (0%)
Cerebral abnormalities 6/18 (33%) 6/11 (55%) 0/7 (0%)
Cardiac malformations 10/15 (66%) 9/12 (75%) 1/3 (33%)
Renal malformations 5/17 (29%) 5/13 (38%) 0/4 (0%)
Genital malformations 5/24 (21%) 5/13 (38%) 0/11 (0%)
Hearing impairment 3/24 (12%) 3/13 (23%) 0/11 (0%)
Visual impairment 4/24 (17%) 3/13 (23%) 1/11 (9%)
Scoliosis 3/24 (12%) 3/13 (23%) 0/11 (0%)
Dysplastic nails 8/24 (33%) 8/13 (62%) 0/11 (0%)
Lower-limb hyperreflexia 5/24 (21%) 1/13 (8%) 4/11 (36%)
Lacrimal-duct aplasia 3/24 (12%) 1/13 (8%) 2/11 (18%)
Accessory nipple 4/24 (17%) 3/13 (23%) 1/11 (9%)
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disease. Future in vitro and in vivo studies on variants inside
and outside the main cluster will be required if we are to
determine which gene expression changes are connected
to which TRRAP-related specific phenotypes.
Supplemental Data
Supplemental Data can be foundwith this article online at https://
doi.org/10.1016/j.ajhg.2019.01.010.
Acknowledgments
We would like to thank all families for participating in this study.
This work was supported in part by grants from: the French
Ministry of Health and the Health Regional Agency from Poitou-
Charentes (HUGODIMS, 2013, RC14_0107) to S.B.; the National
Institute of Neurological Disorders and Stroke (The Epilepsy Phe-
nome/Genome Project NS053998; Epi4K NS077364, NS077274,
NS077303, and NS077276) to D.L. and D.B.G.; the National Insti-
tutes of Health/Eunice Kennedy Shriver National Institute of
Child Health and Human Development grant (HD064667) to
D.A.S.; NINDS R35 NS105078 to J.R.L.; the National Human
Genome Research Institute (NHGRI) and National Heart, Lung,
and Blood Institute (NHLBI) to the Baylor-Hopkins Center for
Mendelian Genomics (UM1 HG006542); NHGRI K08 HG008986
to J.E.P.; the Duke Genome Sequencing Clinic to V.S. and J.S.;
the intramural research program of the NHGRI (grant HG200328
12) to L.G.B., J.J.J., and J.C.S.; the US National Institute of Mental
Health grant R01MH101221 to E.E.E.; the Kids Brain Health
Network and Dart NeuroScience to F.B.; and Mining for Miracles,
British Columbia Children’s Hospital Foundation, and Genome
British Columbia to the CAUSES Study. We thank the Canadian
Institutes of Health Research (CIHR) and Fonds de la recherche
en sante´ du Que´bec (FRSQ) for clinician-scientist awards to
P.M.C.; and the Mayo Clinic Center for Individualized Medicine
(CIM) for supporting this research through the CIM Investigative
and Functional Genomics Program. We are grateful to the mem-
bers of the Canadian Center for Computational Genomics and
the McGill University and Ge´nome Que´bec Innovation Center
for their help in bioinformatics analysis.
Declaration of Interests
E.E.E. is on the scientific advisory board of DNAnexus. The Depart-
ment of Molecular and Human Genetics at Baylor College of
Medicine receives revenue for clinical genetic testing completed
at Baylor Genetics Laboratory. K.M., K.R., J.Z., M.D., A.T., A.B.,
and I.M.W. are employees of GeneDx, Inc. Dr. Goldstein is
Founder and holds equity in Pairnomix and Praxis Therapeutics.
Dr. Goldstein is not aware of any overlap with Pairnomix or Praxis
Therapeutics.
Received: July 16, 2018
Accepted: January 18, 2019














1. Bowman, G.D., and Poirier, M.G. (2015). Post-translational
modifications of histones that influence nucleosome dy-
namics. Chem. Rev. 115, 2274–2295.
2. Venkatesh, S., and Workman, J.L. (2015). Histone exchange,
chromatin structure and the regulation of transcription. Nat.
Rev. Mol. Cell Biol. 16, 178–189.
3. Hunt, C.R., Ramnarain, D., Horikoshi, N., Iyengar, P., Pandita,
R.K., Shay, J.W., and Pandita, T.K. (2013). Histone modifica-
tions and DNA double-strand break repair after exposure to
ionizing radiations. Radiat. Res. 179, 383–392.
4. Legube, G., and Trouche, D. (2003). Regulating histone acetyl-
transferases and deacetylases. EMBO Rep. 4, 944–947.
5. Berndsen, C.E., and Denu, J.M. (2008). Catalysis and substrate
selection by histone/protein lysine acetyltransferases. Curr.
Opin. Struct. Biol. 18, 682–689.
6. McMahon, S.B., Van Buskirk, H.A., Dugan, K.A., Copeland,
T.D., and Cole, M.D. (1998). The novel ATM-related protein
TRRAP is an essential cofactor for the c-Myc and E2F oncopro-
teins. Cell 94, 363–374.
7. Vassilev, A., Yamauchi, J., Kotani, T., Prives, C., Avantaggiati,
M.L., Qin, J., and Nakatani, Y. (1998). The 400 kDa subunit
of the PCAF histone acetylase complex belongs to the ATM su-
perfamily. Mol. Cell 2, 869–875.
8. Park, J., Kunjibettu, S., McMahon, S.B., and Cole, M.D. (2001).
The ATM-related domain of TRRAP is required for histone ace-
tyltransferase recruitment and Myc-dependent oncogenesis.
Genes Dev. 15, 1619–1624.
9. Zhao, L.-J., Loewenstein, P.M., and Green, M. (2017).
Enhanced MYC association with the NuA4 histone acetyl-
transferase complex mediated by the adenovirus E1A N-termi-
nal domain activates a subset of MYC target genes highly
expressed in cancer cells. Genes Cancer 8, 752–761.
10. Jethwa, A., S1abicki, M., Hu¨llein, J., Jentzsch, M., Dalal, V.,
Rabe, S., Wagner, L., Walther, T., Klapper, W., Bohnenberger,
H., et al.; MMML Network Project (2018). TRRAP is essential
for regulating the accumulation of mutant and wild-type
p53 in lymphoma. Blood 131, 2789–2802.
11. Wei, X., Walia, V., Lin, J.C., Teer, J.K., Prickett, T.D., Gartner, J.,
Davis, S., Stemke-Hale, K., Davies, M.A., Gershenwald, J.E.,
et al.; NISC Comparative Sequencing Program (2011). Exome
sequencing identifies GRIN2A as frequently mutated in mela-
noma. Nat. Genet. 43, 442–446.
12. Wurdak, H., Zhu, S., Romero, A., Lorger, M., Watson, J.,
Chiang, C.-Y., Zhang, J., Natu, V.S., Lairson, L.L., Walker,
J.R., et al. (2010). An RNAi screen identifies TRRAP as a regu-
lator of brain tumor-initiating cell differentiation. Cell Stem
Cell 6, 37–47.
13. Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto,
M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I.,
et al. (2007). Genome-wide array-based comparative genomic
The American Journal of Human Genetics 104, 530–541, March 7, 2019 539
hybridization analysis of pancreatic adenocarcinoma: identifi-
cation of genetic indicators that predict patient outcome.
Cancer Sci. 98, 392–400.
14. Herceg, Z., Hulla, W., Gell, D., Cuenin, C., Lleonart, M., Jack-
son, S., and Wang, Z.Q. (2001). Disruption of Trrap causes
early embryonic lethality and defects in cell cycle progression.
Nat. Genet. 29, 206–211.
15. Sawan, C., Hernandez-Vargas, H., Murr, R., Lopez, F., Vaissie`re,
T., Ghantous, A.Y., Cuenin, C., Imbert, J., Wang, Z.-Q., Ren, B.,
and Herceg, Z. (2013). Histone acetyltransferase cofactor Trrap
maintains self-renewal and restricts differentiation of embry-
onic stem cells. Stem Cells 31, 979–991.
16. Tapias, A., Zhou, Z.-W., Shi, Y., Chong, Z., Wang, P., Groth, M.,
Platzer, M., Huttner, W., Herceg, Z., Yang, Y.-G., and Wang,
Z.Q. (2014). Trrap-dependent histone acetylation specifically
regulates cell-cycle gene transcription to control neural pro-
genitor fate decisions. Cell Stem Cell 14, 632–643.
17. Gupta, A.R., Westphal, A., Yang, D.Y.J., Sullivan, C.A.W.,
Eilbott, J., Zaidi, S., Voos, A., Vander Wyk, B.C., Ventola, P.,
Waqar, Z., et al. (2017). Neurogenetic analysis of childhood
disintegrative disorder. Mol. Autism 8, 19.
18. Xu, B., Ionita-Laza, I., Roos, J.L., Boone, B., Woodrick, S., Sun,
Y., Levy, S., Gogos, J.A., and Karayiorgou, M. (2012). De novo
gene mutations highlight patterns of genetic and neural
complexity in schizophrenia. Nat. Genet. 44, 1365–1369.
19. Takata, A., Xu, B., Ionita-Laza, I., Roos, J.L., Gogos, J.A., and
Karayiorgou, M. (2014). Loss-of-function variants in schizo-
phrenia risk and SETD1A as a candidate susceptibility gene.
Neuron 82, 773–780.
20. Geisheker, M.R., Heymann, G., Wang, T., Coe, B.P., Turner,
T.N., Stessman, H.A.F., Hoekzema, K., Kvarnung, M., Shaw,
M., Friend, K., et al. (2017). Hotspots of missense mutation
identify neurodevelopmental disorder genes and functional
domains. Nat. Neurosci. 20, 1043–1051.
21. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A.
(2015). GeneMatcher: A matching tool for connecting investi-
gators with an interest in the same gene. Hum. Mutat. 36,
928–930.
22. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks,
E., Fennell, T., O’Donnell-Luria, A.H., Ware, J.S., Hill, A.J.,
Cummings, B.B., et al.; Exome Aggregation Consortium
(2016). Analysis of protein-coding genetic variation in
60,706 humans. Nature 536, 285–291.
23. Kircher, M., Witten, D.M., Jain, P., O’Roak, B.J., Cooper, G.M.,
and Shendure, J. (2014). A general framework for estimating
the relative pathogenicity of human genetic variants. Nat.
Genet. 46, 310–315.
24. Kumar, P., Henikoff, S., and Ng, P.C. (2009). Predicting the ef-
fects of coding non-synonymous variants on protein function
using the SIFT algorithm. Nat. Protoc. 4, 1073–1081.
25. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gera-
simova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R.
(2010). A method and server for predicting damaging
missense mutations. Nat. Methods 7, 248–249.
26. Ware, J.S., Samocha, K.E., Homsy, J., and Daly, M.J. (2015). In-
terpreting de novo variation in human disease using denovo-
lyzeR. Curr. Protoc. Hum. Genet. 87, 7.25.1–7.25.15.
27. Lelieveld, S.H., Wiel, L., Venselaar, H., Pfundt, R., Vriend, G.,
Veltman, J.A., Brunner, H.G., Vissers, L.E.L.M., and Gilissen,
C. (2017). Spatial clustering of de novo missense mutations
identifies candidate neurodevelopmental disorder-associated
genes. Am. J. Hum. Genet. 101, 478–484.
28. Ferry, Q., Steinberg, J., Webber, C., FitzPatrick, D.R., Ponting,
C.P., Zisserman, A., and Nella˚ker, C. (2014). Diagnostically
relevant facial gestalt information from ordinary photos. eLife
3, e02020.
29. Reijnders, M.R.F., Janowski, R., Alvi, M., Self, J.E., van Essen,
T.J., Vreeburg, M., Rouhl, R.P.W., Stevens, S.J.C., Stegmann,
A.P.A., Schieving, J., et al. (2018). PURA syndrome: clinical
delineation and genotype-phenotype study in 32 individuals
with reviewof published literature. J.Med.Genet.55, 104–113.
30. Murr, R., Vaissie`re, T., Sawan, C., Shukla, V., and Herceg, Z.
(2007). Orchestration of chromatin-based processes: Mind
the TRRAP. Oncogene 26, 5358–5372.
31. Chen, P.B., Hung, J.-H., Hickman, T.L., Coles, A.H., Carey, J.F.,
Weng, Z., Chu, F., and Fazzio, T.G. (2013). Hdac6 regulates
Tip60-p400 function in stem cells. eLife 2, e01557.
32. Fazzio, T.G., Huff, J.T., and Panning, B. (2008). An RNAi screen
of chromatin proteins identifies Tip60-p400 as a regulator of
embryonic stem cell identity. Cell 134, 162–174.
33. Acharya, D., Hainer, S.J., Yoon, Y., Wang, F., Bach, I., Rivera-
Pe´rez, J.A., and Fazzio, T.G. (2017). KAT-independent gene
regulation by Tip60 promotes ESC self-renewal but not plurip-
otency. Cell Rep. 19, 671–679.
34. Tapias, A., and Wang, Z.-Q. (2017). Lysine acetylation and de-
acetylation in brain development and neuropathies. Geno-
mics Proteomics Bioinformatics 15, 19–36.
35. Clayton-Smith, J., O’Sullivan, J., Daly, S., Bhaskar, S., Day, R.,
Anderson, B., Voss, A.K., Thomas, T., Biesecker, L.G., Smith, P.,
et al. (2011). Whole-exome-sequencing identifies mutations
in histone acetyltransferase gene KAT6B in individuals with
the Say-Barber-Biesecker variant of Ohdo syndrome. Am. J.
Hum. Genet. 89, 675–681.
36. Szakszon, K., Salpietro, C., Kakar, N., Knegt, A.C., Ola´h, E´.,
Dallapiccola, B., and Borck, G. (2013). De novo mutations of
the gene encoding the histone acetyltransferase KAT6B in
two patients with Say-Barber/Biesecker/Young-Simpson syn-
drome. Am. J. Med. Genet. A. 161A, 884–888.
37. Yilmaz, R., Beleza-Meireles, A., Price, S., Oliveira, R., Kubisch,
C., Clayton-Smith, J., Szakszon, K., and Borck, G. (2015).
A recurrent synonymous KAT6B mutation causes Say-Barber-
Biesecker/Young-Simpson syndrome by inducing aberrant
splicing. Am. J. Med. Genet. A. 167A, 3006–3010.
38. Campeau, P.M., Kim, J.C., Lu, J.T., Schwartzentruber, J.A.,
Abdul-Rahman, O.A., Schlaubitz, S., Murdock, D.M., Jiang,
M.-M., Lammer, E.J., Enns, G.M., et al. (2012). Mutations in
KAT6B, encoding a histone acetyltransferase, cause Genitopa-
tellar syndrome. Am. J. Hum. Genet. 90, 282–289.
39. Simpson, M.A., Deshpande, C., Dafou, D., Vissers, L.E.L.M.,
Woollard, W.J., Holder, S.E., Gillessen-Kaesbach, G., Derks,
R., White, S.M., Cohen-Snuijf, R., et al. (2012). De novomuta-
tions of the gene encoding the histone acetyltransferase
KAT6B cause Genitopatellar syndrome. Am. J. Hum. Genet.
90, 290–294.
40. Millan, F., Cho, M.T., Retterer, K., Monaghan, K.G., Bai, R., Vi-
tazka, P., Everman, D.B., Smith, B., Angle, B., Roberts, V., et al.
(2016). Whole exome sequencing reveals de novo pathogenic
variants in KAT6A as a cause of a neurodevelopmental disor-
der. Am. J. Med. Genet. A. 170, 1791–1798.
41. Murray, C.R., Abel, S.N., McClure, M.B., Foster, J., 2nd, Walke,
M.I., Jayakar, P., Bademci, G., and Tekin, M. (2017). Novel
causative variants in DYRK1A, KARS, and KAT6A associated
with intellectual disability and additional phenotypic fea-
tures. J. Pediatr. Genet. 6, 77–83.
540 The American Journal of Human Genetics 104, 530–541, March 7, 2019
42. Yan, K., Rousseau, J., Littlejohn, R.O., Kiss, C., Lehman, A.,
Rosenfeld, J.A., Stumpel, C.T.R., Stegmann, A.P.A., Robak, L.,
Scaglia, F., et al.; DDD Study; and CAUSES Study (2017). Mu-
tations in the chromatin regulator gene BRPF1 cause syn-
dromic intellectual disability and deficient histone acetyla-
tion. Am. J. Hum. Genet. 100, 91–104.
43. Roelfsema, J.H., White, S.J., Ariyu¨rek, Y., Bartholdi, D., Nied-
rist, D., Papadia, F., Bacino, C.A., den Dunnen, J.T., van
Ommen, G.-J.B., Breuning, M.H., et al. (2005). Genetic hetero-
geneity in Rubinstein-Taybi syndrome: Mutations in both the
CBP and EP300 genes cause disease. Am. J. Hum. Genet. 76,
572–580.
44. Bartholdi, D., Roelfsema, J.H., Papadia, F., Breuning, M.H.,
Niedrist, D., Hennekam, R.C., Schinzel, A., and Peters,
D.J.M. (2007). Genetic heterogeneity in Rubinstein-Taybi syn-
drome: Delineation of the phenotype of the first patients car-
rying mutations in EP300. J. Med. Genet. 44, 327–333.
45. Tsai, A.C., Dossett, C.J., Walton, C.S., Cramer, A.E., Eng, P.A.,
Nowakowska, B.A., Pursley, A.N., Stankiewicz, P., Wiszniew-
ska, J., and Cheung, S.W. (2011). Exon deletions of the
EP300 and CREBBP genes in two children with Rubinstein-
Taybi syndrome detected by aCGH. Eur. J. Hum. Genet. 19,
43–49.
46. Negri, G., Milani, D., Colapietro, P., Forzano, F., Della Monica,
M., Rusconi, D., Consonni, L., Caffi, L.G., Finelli, P., Scarano,
G., et al. (2015). Clinical andmolecular characterization of Ru-
binstein-Taybi syndrome patients carrying distinct novel mu-
tations of the EP300 gene. Clin. Genet. 87, 148–154.
47. Xu, L.-M., Li, J.-R., Huang, Y., Zhao, M., Tang, X., and Wei, L.
(2012). AutismKB: An evidence-based knowledgebase of
autism genetics. Nucleic Acids Res. 40, D1016–D1022.
48. Piton, A., Jouan, L., Rochefort, D., Dobrzeniecka, S., Lacha-
pelle, K., Dion, P.A., Gauthier, J., and Rouleau, G.A. (2013).
Analysis of the effects of rare variants on splicing identifies al-
terations in GABAA receptor genes in autism spectrum disor-
der individuals. Eur. J. Hum. Genet. 21, 749–756.
49. Lang, B., Alrahbeni, T.M., Clair, D.S., Blackwood, D.H., Inter-
national Schizophrenia Consortium, McCaig, C.D., and
Shen, S. (2011). HDAC9 is implicated in schizophrenia and ex-
pressed specifically in post-mitotic neurons but not in adult
neural stem cells. Am. J. Stem Cells 1, 31–41.
50. Severinsen, J.E., Bjarkam, C.R., Kiaer-Larsen, S., Olsen, I.M.,
Nielsen,M.M., Blechingberg, J., Nielsen, A.L., Holm, I.E., Fold-
ager, L., Young, B.D., et al. (2006). Evidence implicating BRD1
with brain development and susceptibility to both schizo-
phrenia and bipolar affective disorder. Mol. Psychiatry 11,
1126–1138.
51. Gause, M., Eissenberg, J.C., Macrae, A.F., Dorsett, M., Misulo-
vin, Z., and Dorsett, D. (2006). Nipped-A, the Tra1/TRRAP
subunit of the Drosophila SAGA and Tip60 complexes, has
multiple roles in Notch signaling during wing development.
Mol. Cell. Biol. 26, 2347–2359.
52. Ceol, C.J., and Horvitz, H.R. (2004). A new class of C. ele-
gans synMuv genes implicates a Tip60/NuA4-like HAT com-
plex as a negative regulator of Ras signaling. Dev. Cell 6,
563–576.
53. Finkbeiner, M.G., Sawan, C., Ouzounova, M., Murr, R., and
Herceg, Z. (2008). HAT cofactor TRRAP mediates beta-catenin
ubiquitination on the chromatin and the regulation of the ca-
nonical Wnt pathway. Cell Cycle 7, 3908–3914.
54. Knutson, B.A., and Hahn, S. (2011). Domains of Tra1 impor-
tant for activator recruitment and transcription coactivator
functions of SAGA and NuA4 complexes. Mol. Cell. Biol. 31,
818–831.
55. Zhou, X., Edmonson, M.N., Wilkinson, M.R., Patel, A., Wu,
G., Liu, Y., Li, Y., Zhang, Z., Rusch, M.C., Parker, M., et al.
(2016). Exploring genomic alteration in pediatric cancer using
ProteinPaint. Nat. Genet. 48, 4–6.
56. Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., and
Sternberg, M.J.E. (2015). The Phyre2 web portal for
protein modeling, prediction and analysis. Nat. Protoc.
10, 845–858.
57. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S.,
Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. (2004). UCSF
Chimera—A visualization system for exploratory research
and analysis. J. Comput. Chem. 25, 1605–1612.
The American Journal of Human Genetics 104, 530–541, March 7, 2019 541
